Perspective · 2 Feb 2026
Conference abstractPublished 20 Nov 2013
Brucine, an indole alkaloid from Strychnos nux-vomica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis
King Saud University, Saudi Arabia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Angiogenesis blockade has been shown to be an effective strategy in inhibiting tumor growth and metastasis. Considering anti-angiogenesis therapy is to target endothelial cells that support tumor growth rather than cancer cells themselves, VEGFR-2 has become an important therapeutic target for cancer anti-angiogenesis therapy. Preliminary reports suggest that brucine possesses anti-tumor activity. However, its roles in tumor angiogenesis and the involved molecular mechanism are still unknown to make a firm conclusion before implementing it into the clinical practice. Therefore, we examined its anti-angiogenic effects and mechanisms in vitro and in vivo. Human umbilical vein endothelial cells (HUVECs) were treated with or without VEGF and different concentrations of brucine, then tested for cell viability, migration, tube formation and apoptosis. The role of VEGFR2-mediated signaling pathway in brucine-inhibited angiogenesis was evaluated using quantitative real-time PCR (qRT-PCR) and Western blotting. In vivo antiangiogenic activity was determined using sponge implant angiogenesis assay and antitumor activity was evaluated against Ehrlich ascites carcinoma tumor. Tumor volume, cell viability, anti-angiogenic and anti-inflammatory factors were determined. Immunohistochemistry analysis for CD-31, P-VEGFR2, P-Akt, and P-Erk was also performed. One-way analysis of variance (ANOVA) was used to determine the statistical significance of the difference between means. Brucine significantly inhibited a series of VEGF-induced angiogenesis processes including proliferation, migration, and tube formation in HUVECs and inhibited neovascularization in sponge implant angiogenesis assay and tumor growth in vivo via suppressing VEGF-induced phosphorylation of VEGFR2. Brucine inhibited VEGFR-2 tyrosine kinase activity (IC50=21.34 Ã?¼M) and further inhibited angiogenesis via inhibition of VEGFR2-mediated signaling with the involvement of some key kinases such as c-Src, FAK, ERK, AKT, mTOR and S6K and induction of apoptosis. Brucine acts as a potent VEGFR2 kinase inhibitor, and exerts the anti-angiogenic activity at least in part through VEGFR2-mediated signaling pathway.
Subjects
BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cell Science & Therapy.
Commentary · 2 Feb 2026
Metabolism Regulation and Its Influence on Therapeutic Development in Human Disease
Commentary · 2 Dec 2025
Cellular Membranes and Transport Proteins as Regulators of Homeostasis and Metabolic Coordination
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cell Science & Therapy
- SubjectBiology
- BylineArticles whose byline prints “Sarita Saraswati”
